Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue

Phase 4CompletedNCT01937312

Alcon Research282 enrolled

Overview

The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy.

This study was divided into 2 sequential phases. The Screening/Eligibility Phase included one Screening Visit and two Eligibility Visits, during which subjects washed out of all other intraocular pressure (IOP)-lowering medications and dosed with TRAVATAN Z®, XALATAN®, or LUMIGAN®, 1 drop instilled in each eye once daily for 28 days. Subjects who met all inclusion/exclusion criteria were randomized at the second Eligibility Visit. The Treatment Phase consisted of two on-therapy visits (Week 2 and Week 6).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

282

Conditions

Ocular Hypertension Open Angle Glaucoma

Interventions

Brinzolamide 1%/brimonidine 0.2% ophthalmic suspensionDRUG

VehicleDRUG

Inactive ingredients used as a placebo comparator

Prostaglandin analogueDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of open angle glaucoma (including open-angle glaucoma with pseudoexfoliation or pigment dispersion) or ocular hypertension; * Mean intraocular pressure (IOP) measurements in at least 1 eye (study eye) of ≥ 21 mmHg and \<32 mmHg at 2 consecutive visits (Eligibility 1 and Eligibility 2); * Previously prescribed TRAVATAN Z® 0.004%, XALATAN® 0.005%, or LUMIGAN® 0.01% monotherapy for at least 28 days prior to the Screening Visit; * Able to understand and sign Informed Consent Document; * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Women of childbearing potential who are pregnant, breastfeeding, or do not agree to use an adequate birth control method throughout the study; * Any form of glaucoma other than open angle glaucoma or ocular hypertension; * Severe central visual field loss; * Chronic, recurrent, or severe inflammatory eye disease; * Ocular trauma within the past 6 months; * Ocular infection or ocular inflammation within the past 3 months; * Best-corrected visual acuity score worse than approximately 20/80 Snellen; * Eye surgery within the past 6 months; * Any condition, including severe illness, which would make the subject unsuitable for the study in the opinion of the Investigator; * Use of any additional topical or systemic ocular hypertensive medication during the study; * Patients who, in the opinion of the Investigator, cannot discontinue all IOP-lowering ocular medication(s) per the appropriate washout schedule prior to Eligibility 1 Visit; * Other protocol-defined exclusion criteria may apply.

Outcomes

Primary Outcomes

Mean Diurnal Intraocular Pressure (IOP) at Week 6

Diurnal IOP was defined as the average of the four timepoints measured (8 AM, 10 AM, 3 PM, and 5 PM). IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in millimeters mercury (mmHg). One eye was chosen as the study eye and only data for the study eye were used for the analysis. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).

Time frame: Week 6

Secondary Outcomes

Mean Diurnal IOP Change From Baseline to Week 6

Baseline IOP was defined as the average of the timepoint-matched IOP measurements at Eligibility 1 and Eligibility 2 Visits. Diurnal IOP change was defined as the average of the four changes from baseline (timepoints 8 AM, 10 AM, 3 PM, and 5 PM). IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in millimeters mercury (mmHg). One eye was chosen as the study eye and only data for the study eye were used for the analysis. A more negative change from baseline indicates a greater improvement, i.e., a reduction of IOP.

Time frame: Baseline, Week 6

Mean Diurnal IOP Percentage Change From Baseline to Week 6

Baseline IOP was defined as the average of the timepoint-matched IOP measurements at Eligibility 1 and Eligibility 2 Visits. Diurnal IOP Percentage Change was defined as the average of the four percent changes from baseline (timepoints 8 AM, 10 AM, 3 PM, and 5 PM). IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in millimeters mercury (mmHg). One eye was chosen as the study eye and only data for the study eye were used for the analysis. A more negative percent change from baseline indicates a greater amount of improvement, i.e., a reduction of IOP.

Time frame: Baseline, Week 6

Mean IOP at Week 6 for Each Time Point (8 AM, 10 AM, 3 PM, 5 PM)

IOP was assessed using Goldmann applanation tonometry and reported in mmHg. One eye was chosen as the study eye and only data for the study eye were used for the analysis. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.